SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    International Agency for Research on Cancer (IARC). GLOBOCAN 2008, version 1.2: Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: IARC; 2010. Available at: http://globocan.iarc.fr. [Accessed April 30, 2012].
  • 2
    Australian Institute of Health and Welfare (AIHW). Australia's Health 2010. No. 12, Catalog no. AUS 122. Canberra, Australia: AIHW; 2010. Available at: http://www.aihw.gov.au. [Accessed April 30, 2012].
  • 3
    Shellnut JK, Wasvary HJ, Grodsky MB, Boura JA, Priest SG. Evaluating the age distribution of patients with colorectal cancer: are the United States Preventive Services Task Force guidelines for colorectal cancer screening appropriate? Dis Colon Rectum. 2010; 53: 58.
  • 4
    Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004; 22: 12091214.
  • 5
    Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22: 229237.
  • 6
    Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol. 2005; 23: 94419442.
  • 7
    Foster JA, Salinas GD, Mansell D, Williamson JC, Casebeer LL. How does older age influence oncologists' cancer management? Oncologist. 2010; 15: 584592.
  • 8
    Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004; 15: 13301338.
  • 9
    Blanke CD, Bot BM, Thomas DM, et al. Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from 9 first-line phase III chemotherapy trials. J Clin Oncol. 2011; 29: 27812786.
  • 10
    Golfinopoulos V, Pentheroudakis G, Pavlidis N. Treatment of colorectal cancer in the elderly: a review of the literature. Cancer Treat Rev. 2006; 32: 18.
  • 11
    Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med. 2002; 136: 349357.
  • 12
    McKibbin T, Frei CR, Greene RE, Kwan P, Simon J, Koeller JM. Disparities in the use of chemotherapy and monoclonal antibody therapy for elderly advanced colorectal cancer patients in the community oncology setting. Oncologist. 2008; 13: 876885.
  • 13
    Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007; 370: 143152.
  • 14
    Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007; 370: 135142.
  • 15
    Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. Lancet Oncol. 2011; 12: 10321044.
  • 16
    Price TJ, Zannino D, Wilson K, et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Ann Oncol. 2012; 23: 15311536.
  • 17
    Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX Study. J Clin Oncol. 2010; 28: 31913198.
  • 18
    Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007; 357: 20402048.
  • 19
    Jehn CF, Boning L, Kroning H, Possinger K, Luftner D. Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer. 2012; 106: 274278.
  • 20
    Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004; 22: 46264631.
  • 21
    Balducci L. New paradigms for treating elderly patients with cancer: the comprehensive geriatric assessment and guidelines for supportive care. J Support Oncol. 2003; 1( 4 suppl 2): 3037.
  • 22
    Soubeyran P, Fonck M, Blanc-Bisson C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol. 2012; 30: 18291834.